Ron Feldman, MD
Dermatology · Atlanta, GANPI 1316123821
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,380 of the $28,603 with a category attached, or 95.7%. 6 manufacturers reported payments, led by Astrazeneca UK Limited at 29.3% of the total. 2023 is the largest year on record at $10,192, 3.2 times the $3,139 reported in 2019. Among dermatology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $1100.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$8K
- Janssen Research & Development, LLC$7K
- Argenx US, Inc.$6K
- Galderma Laboratories, L.p.$5K
- Grifols, S.A.$2K
- Incyte Corporation$13
Across 14 payments — averaging $32,454 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$325K
- Astrazeneca UK Limited$102K
- Sanofi US Services Inc.$23K
- Principia Biopharma Inc.$5K
What the payments were for
- Consulting fees$27,38096%
- Travel & lodging$8383%
- Food & beverage$3731%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 12 | $8,387 |
| Janssen Research & Development, LLC | 4 | $7,440 |
| Argenx US, Inc. | 2 | $5,625 |
| Galderma Laboratories, L.p. | 4 | $5,139 |
| Grifols, S.A. | 3 | $2,000 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,603 in reported general payments places this provider in the 90th percentile of 345 dermatology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 24 | $491,643 |
| Dupixent PenDupilumab | 86 | $401,653 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 18 | $386,504 |
| Humira(Cf) PenAdalimumab | 15 | $382,445 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $261,055 |
| OtezlaApremilast | 27 | $123,355 |
| EnbrelEtanercept | 14 | $110,974 |
| Mycophenolate Mofetil | 152 | $31,379 |
| Dapsone | 93 | $8,349 |
| Doxycycline Hyclate | 34 | $7,705 |
| Clobetasol Propionate | 111 | $5,495 |
| Cyclosporine | 12 | $2,781 |
| MethotrexateMethotrexate Sodium | 109 | $2,635 |
| Tacrolimus | 29 | $2,310 |
| Triamcinolone Acetonide | 122 | $1,885 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Atlanta
- Zakiya RiceAtlanta$1.1M
- Joseph PayneAtlanta$711K
- Jamie WeismanAtlanta$620K
- Mack RachalAtlanta$260K
- Sumayah TaliaferroAtlanta$104K
- Sarah ChisolmAtlanta$59K
- Anna PareAtlanta$58K
- Lauren OrensteinAtlanta$52K
- Chelsie RogersAtlanta$43K
- Christine LawAtlanta$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.